Sanuwave Health Inc (SNWV) valuation
Sanuwave Health P/E ratio history
Sanuwave Health trades at 5.6 times its earnings over the last twelve months.
| Fiscal year ended | Price | EPS | P/E |
|---|---|---|---|
| Dec 31, 2025 | $29.84 | — | n/m |
| Dec 31, 2024 | $23.00 | -$7.41 | n/m |
| Dec 31, 2023 | $4.87 | -$12.19 | n/m |
| Dec 31, 2022 | $8.55 | — | n/m |
| Dec 31, 2021 | $63.75 | — | n/m |
| Dec 31, 2020 | $69.37 | — | n/m |
| Dec 31, 2019 | $60.00 | — | n/m |
n/m: not meaningful (a loss, or earnings close to zero). The daily P/E line is a chart indicator in the app.
Sanuwave Health valuation against its peers
| Company | Market value | P/E | Price / sales |
|---|---|---|---|
| Sanuwave HealthSNWV | $44.0M | 5.6 | 1.0 |
| BioteBTMD | $42.0M | 11.1 | 0.2 |
| MyomoMYO | $48.0M | — | 1.1 |
| Inmune BioINMB | $39.0M | — | — |
| CvrxCVRX | $37.0M | — | 0.6 |
| Heron TherapeuticsHRTX | $53.0M | — | 0.4 |
| Aldeyra TherapeuticsALDX | $34.0M | — | — |
| Cardiff OncologyCRDF | $61.0M | — | 120.1 |
| Aardvark TherapeuticsAARD | $30.0M | — | — |
| Peer median | 11.1 | 0.6 |
Reading these multiples
The P/E divides the share price by earnings per share over the last twelve months; the forward P/E divides it by the earnings analysts expect over the next twelve. Price to sales compares the company's market value with its revenue over the last twelve months. A multiple reads differently from one industry to the next, so the peer group above is the fairer comparison.
See also: SNWV financials · SNWV returns
No forecast, no recommendation. This page describes Sanuwave Health Inc from published data; it is not advice to buy, sell or hold any security.
Figures as of the close on Oct 30, 2026 unless a row says otherwise. Prices are split adjusted; returns include dividends reinvested. Data may be delayed. See the disclaimer and how TrendArc works.